Active, Not Recruiting
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
NCT06284564
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
- Locations
-
- UT Southwestern Medical Center Dallas, Texas, United States
- MD Anderson Cancer Center Houston, Texas, United States